News & Updates

Show Multimedia Only
Personalized mRNA cancer vaccine + pembrolizumab hits targets in phase III melanoma trial

Personalized mRNA cancer vaccine + pembrolizumab hits targets in phase III melanoma trial

10 Nov 2026 byAudrey Abella

In the large phase III INTerpath-001 study evaluating individuals with resected stage IIB–IV melanoma, recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) improved when the mRNA-based individualized neoantigen therapy intismeran autogene was added to pembrolizumab compared with pembrolizumab alone.

10 Nov 2026